N/A
N=11
Electromyography in Patients on Chronic Pyridostigmine Therapy
Muscle Weakness
Bottom Line
View on ClinicalTrials.gov: NCT02364180 ↗Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcome: Primary: Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response — 0 percent change
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Electromyography (EMG) (Diagnostic_test)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- University of Toledo Health Science Campus
- Primary completion
- Jul 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response |
— | — |
Summary
We intend to measure evoked EMG at two sites in subjects who are chronically taking pyridostigmine.
Eligibility Criteria
Inclusion Criteria
- Subjects who have been taking pyridostigmine for the treatment of any condition other than myasthenia gravis
Exclusion Criteria
- Subjects taking pyridostigmine for the treatment of myasthenia gravis will be excluded.
Data sourced from ClinicalTrials.gov (NCT02364180). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.